Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans

Pharmacotherapy

Volumn 36, Issue 11, 2016, Pages 1173-1179

  Britnell, Sara R ^a   Willets, Amy E ^a   Vanderman, Adam J ^a   Woodard, Catherine L ^a   Britt, Rachel B ^a  

^a DURHAM VA HEALTH CARE SYSTEM   (United States)

Author keywords

chronic; drug interactions; hepatitis C; ledipasvir; ribavirin; sofosbuvir; veterans; warfarin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; ENOXAPARIN; HEMOGLOBIN; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; WARFARIN; ANTICOAGULANT AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ARTICLE; ATRIAL FIBRILLATION; CASE REPORT; CASE STUDY; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG OVERDOSE; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; HEMATURIA; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER FUNCTION; LUNG EMBOLISM; MIDDLE AGED; MITRAL VALVE REPLACEMENT; NONHUMAN; PORTAL HYPERTENSION; STOMACH DISEASE; TREATMENT OUTCOME; TREND STUDY; UPPER GASTROINTESTINAL BLEEDING; VETERAN; ANALOGS AND DERIVATIVES; DRUG INTERACTION; HEPATITIS C, CHRONIC; MALE; ORGANIZATION AND MANAGEMENT; PHARMACIST; PHARMACY;

AGED; ANTICOAGULANTS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PHARMACEUTICAL SERVICES; PHARMACISTS; RIBAVIRIN; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VETERANS; WARFARIN;

EID: 84995784266     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1845     Document Type: Article

References (18)

1. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, national health and nutrition examination survey 2003 to 2010. Ann Intern Med 2014;160(5):293–300.
2. Wang LS, D'Souza LS, Jacobson IM. Hepatitis C—a clinical review. J Med Virol 2016;88(11):1844–55.
3. VA Expands Hepatitis C Drug Treatment [news release]. Washington, DC: U.S. Department of Veterans Affairs, Office of Public Affairs Media Relations. Available from http://www.va.gov/opa/pressrel/includes/viewPDF.cfm?id=2762. Accessed March 9, 2016.
4. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available from http://www.hcvguidelines.org. Accessed May 22, 2016.
5. Gilead Sciences, Inc. Harvoni—ledipasvir and sofosbuvir tablet, film coated, package insert. Foster City, CA; 2016.
6. Amneal Pharmaceuticals. Warfarin sodium package insert. Glasgow, KY; 2011.
7. Haines ST, Dowling T, Harvey RD. Warfarin. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. New York, NY: Lippincott Williams & Wilkins, 2006:715–51.
8. de Lorenzo-Pinto A, Giménez-Manzorro Á, Rodríguez-González CG, et al. Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration. J Clin Pharm Ther 2016;41(4):444–6.
9. Schulman S. Inhibition of warfarin activity by ribavirin. Ann Pharmacother 2002;36(1):72–4.
10. Gatti DC, Cha A. Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection. Am J Health Syst Pharm 2012;69(23):2062–5.
11. Tsiattalos AS, Patel A. Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report. J Med Case Rep 2014;8:433.
12. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41(4):674–80.
13. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239–45.
14. Gilead Sciences International Limited. European Medicines Agency. Harvoni (ledipasvir/sofosbuvir) film-coated tablets package insert. Cambridge, UK; 2014.
15. Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int 2015;35(1):30–6.
16. Casado JL, Esteban MA, Bañón S, et al. Fibrosis regression explains differences in outcome in HIV-/HCV-coinfected patients with cirrhosis after sustained virological response. Dig Dis Sci 2015;60(11):3473–81.
17. Lewis JH, Stine JG. Prescribing medications in patients with cirrhosis: a practical guide. Aliment Pharmacol Ther 2013;37(12):1132–56.
18. Serlin MJ, Mossman S, Sibeon RG, Tempero KF, Breckenridge AM. Interaction between diflunisal and warfarin. Clin Pharmacol Ther 1980;28(4):493–8.